We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSHP Director/PDMR Shareholding February 15, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") Notification of transactions by person discharging managerial responsibilities Details of the person discharging managerial responsibilities 1. ("PDMR") / person closely associated them ("PCA") a) Name Flemming Ornskov, MD, MPH 2. Reason for the notification a) Position / status Chief Executive Officer - PDMR Initial notification / b) amendment Initial notification Details of the issuer, emission allowance participant, 3. auction platform, auctioneer or auction monitor a) Name Shire plc b) LEI 54930005LQRLI2UXRQ59 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 4. where transactions have been conducted Description of the financial instrument, a) type of instrument Shire plc American Depositary Shares ("ADSs") Identification code ISIN: US82481R1068 Release of ADSs awarded under the Shire Executive Annual Incentive on February 13, 2015. In accordance with the relevant plan rules, upon release the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the ADSs from the award date to the date of release. Nature of the (Details of related disposals of ADSs are referenced b) transaction in section 5. below.) c) Price(s) and volume(s) Price(s) Volume(s) $0 2,546 Aggregated information - Aggregated volume d) - Price N/A (single transaction) e) Date of the transaction February 13, 2018 Place of the f) transaction N/A Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 5. where transactions have been conducted Description of the financial instrument, a) type of instrument Shire plc American Depositary Shares ("ADSs") Identification code ISIN: US82481R1068 Automated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds Nature of the of this disposal were used to satisfy personal tax b) transaction liabilities arising from the release of the ADSs. c) Price(s) and volume(s) Price(s) Volume(s) See appendix below Aggregated information - Aggregated volume d) - Price Weighted average price Aggregate volume $132.0104 1,572 e) Date of the transaction February 13, 2018 f) Place of the ARCX / CDRG / CROS / DBAX / EBXL / INET / NITE / NQPX transaction Appendix Place of the transaction Aggregate volume Weighted average price ARCX 369 $132.1072 CDRG 200 $131.9800 CROS 200 $131.9800 DBAX 100 $131.9900 EBXL 100 $131.9850 INET 203 $131.9716 NITE 300 $131.9800 NQPX 100 $131.9900 Total 1,572 $132.0104 Oliver Strawbridge Senior Assistant Company Secretary For further information please contact: Investor Relations Christoph Brackmann christoph.brackmann@shire.com +41 795 432 359 Robert Coates rcoates@shire.com +44 203 549 0874 Sun Kim sun.kim@shire.com +1 617 588 8175 Media Lisa Adler lisa.adler@shire.com +1 617 588 8607 Katie Joyce kjoyce@shire.com +1 781 482 2779 NOTES TO EDITORS About Shire Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest. We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people's lives with medicines that have a meaningful impact on patients and all who support them on their journey. www.shire.com This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Shire plc via Globenewswire
(END) Dow Jones Newswires
February 15, 2018 07:00 ET (12:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Shire Chart |
1 Month Shire Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions